Total Debt Summary of Azitra, Inc.

Azitra, Inc.'s latest annual total debt in 2023 was 885.94 Thousand USD , down -88.54% from previous year.
Azitra, Inc.'s latest quarterly total debt in 2024 Q2 was 722.65 Thousand USD , down -10.17% from previous quarter.
Azitra, Inc. reported annual total debt of 7.72 Million USD in 2022, up 679.05% from previous year.
Azitra, Inc. reported annual total debt of 992.01 Thousand USD in 2021, down 0.0% from previous year.
Azitra, Inc. reported quarterly total debt of 804.49 Thousand USD for 2024 Q1, down -9.19% from previous quarter.
Azitra, Inc. reported quarterly total debt of 959.2 Thousand USD for 2023 Q3, down -3.27% from previous quarter.

Annual Total Debt Chart of Azitra, Inc. (2023 - 2021)

Name	Total Debt	Total Debt Difference
AIM ImmunoTech Inc.	495 Thousand USD	-78.979%
Ampio Pharmaceuticals, Inc.	274 Thousand USD	-223.338%
Armata Pharmaceuticals, Inc.	120.37 Million USD	99.264%
Actinium Pharmaceuticals, Inc.	2.11 Million USD	58.072%
Can-Fite BioPharma Ltd.	39.99 Thousand USD	-2114.923%
Chromocell Therapeutics Corporation	1.26 Million USD	30.168%
Calidi Biotherapeutics, Inc.	7.23 Million USD	87.756%
CEL-SCI Corporation	13.57 Million USD	93.472%
iBio, Inc.	4.46 Million USD	80.136%
Lineage Cell Therapeutics, Inc.	2.95 Million USD	69.988%
MAIA Biotechnology, Inc.	- USD	-Infinity%
Matinas BioPharma Holdings, Inc.	3.55 Million USD	75.086%
Navidea Biopharmaceuticals, Inc.	2.43 Million USD	63.606%
NovaBay Pharmaceuticals, Inc.	2.74 Million USD	67.666%
NanoViricides, Inc.	- USD	-Infinity%
Oragenics, Inc.	312.7 Thousand USD	-183.319%
BiomX Inc.	15.09 Million USD	94.13%
BiomX Inc.	15.09 Million USD	94.13%
Protalix BioTherapeutics, Inc.	26.28 Million USD	96.629%
Palatin Technologies, Inc.	590.33 Thousand USD	-50.075%
Scorpius Holdings, Inc.	14.04 Million USD	93.691%